The association of endoscopic and histologic endpoints with faecal calprotectin and C-reactive protein in patients with moderately to severely active ulcerative colitis treated with mirikizumab

被引：0
|
作者：
Panaccione, R. [1 ]
Sapin, C. [2 ]
Chan-Diehl, F. W. [3 ]
Moses, R. E. [3 ]
Siegmund, B. [4 ]
Walsh, A. [5 ]
Kobayashi, T. [6 ]
Parambir, D. S. [7 ]
Travis, S. [8 ]
机构：
[1] Univ Calgary, Cumming Sch Med, Fac Med, Calgary, AB, Canada
[2] Eli Lilly France, Rheumatol Gastroenterol Real World Access Analyt, Neuilly Sur Seine, France
[3] Eli Lilly & Co, Gastroenterol, Indianapolis, IN USA
[4] Univ Med Berlin, Medizin Klin Gastroenterol Infektiol, Rheumatol Charite, Berlin, Germany
[5] Nuffield Hlth Manor Hosp, Translat Gastroenterol Unit, Oxford, England
[6] Kitasato Univ, Gastroenterol, Kitasato Inst Hosp, Tokyo, Japan
[7] Northwestern Univ, Gastroenterol & Hepatol, Feinberg Sch Med, Chicago, IL USA
[8] Univ Oxford, Nuffield Dept Med, Oxford, England
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP90
引用
收藏
页码：I167 / I168
页数：2
相关论文
共 50 条
  • [21] Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately to severely active Ulcerative Colitis
    Hart, A.
    Martin-Arranz, M. D.
    Laharie, D.
    Matsuoka, K.
    Dhesi, E.
    Redondo, I.
    Baygani, S.
    Zaremba-Pechmann, L.
    Samaan, K.
    Navabi, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I27 - I28
  • [22] EFFECT OF MIRIKIZUMAB ON CLINICAL AND ENDOSCOPIC OUTCOMES AFTER 1 ANTI-TNF FAILURE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Hart, Ailsa
    Martin-Arranz, Maria Dolores
    Laharie, David
    Matsuoka, Katsuyoshi
    Dhesi, Endip
    Redondo, Isabel
    Baygani, Simin
    Zaremba-Pechmann, Liliana
    Samaan, Karen H.
    Navabi, Seyedehsan
    GASTROENTEROLOGY, 2024, 166 (05) : S828 - S828
  • [23] Long-Term Endoscopic and Histological Outcomes of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis With up to 3 Years of Treatment
    Sands, Bruce E.
    Kobayashi, Taku
    Wu, Jianmin
    Wang, Isabella Yali
    Zhu, Baojin
    Redondo, Isabel
    Peyrin-Biroulet, Laurent
    Walsh, Alissa
    Magro, Fernando
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1042 - S1043
  • [24] Correlation of C-Reactive Protein with Clinical and Endoscopic Activity in Patients with Ulcerative Colitis
    Sami Karoui
    Sonia Laz
    Meriem Serghini
    Norsaf Bibani
    Jalel Boubaker
    Azza Filali
    Digestive Diseases and Sciences, 2011, 56 : 1801 - 1805
  • [25] Correlation of C-Reactive Protein with Clinical and Endoscopic Activity in Patients with Ulcerative Colitis
    Karoui, Sami
    Laz, Sonia
    Serghini, Meriem
    Bibani, Norsaf
    Boubaker, Jalel
    Filali, Azza
    DIGESTIVE DISEASES AND SCIENCES, 2011, 56 (06) : 1801 - 1805
  • [26] Impact of Ozanimod on C-Reactive Protein Levels and the Association With OZA Efficacy in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 True North Study
    Harris, Sarah
    Maddux, Rachel
    Wu, Chun
    Hu, Yanhua
    Petersen, AnnKatrin
    Rubin, David T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S868 - S868
  • [27] Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
    Chua, Laiyi
    Friedrich, Stuart
    Zhang, Xin Cindy
    CLINICAL PHARMACOKINETICS, 2023, : 1479 - 1491
  • [28] Trajectories of response in patients with moderately-to-severely active ulcerative colitis treated with mirikizumab: Results from the LUCENT-1 study
    Schreiber, S. W.
    Clemow, D. B.
    Keohane, A.
    Zhu, B.
    Ritter, T.
    Regueiro, M.
    Hudesman, D.
    Chen, Y. F.
    Owen, C.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1975 - I1976
  • [29] Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
    Chua, Laiyi
    Friedrich, Stuart
    Zhang, Xin Cindy
    CLINICAL PHARMACOKINETICS, 2023,
  • [30] Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
    Laiyi Chua
    Stuart Friedrich
    Xin Cindy Zhang
    Clinical Pharmacokinetics, 2023, 62 (10) : 1479 - 1491
12345